Characterization of an MR‐compatible motion platform for quality assurance of motion‐compensated treatments on the 1.5 T MR‐linac
Open Access
- 31 January 2025
- journal article
- research article
- Published by Wiley in Medical Physics
- Vol. 52 (5) , 3391-3397
Abstract
Background: Novel motion‐compensated treatment techniques on the MR‐linac can address adverse intra‐fraction motion effects. These techniques involve beam gating or intra‐fraction adaptations of the treatment plan based on real‐time magnetic resonance imaging (MRI) performed during treatment. For quality assurance (QA) of these workflows, a multi‐purpose motion platform is desirable. This platform should accommodate various phantoms, enabling multiple QA workflows. Purpose: This study aims to evaluate the new IBA QUASAR Motion MR Platform for use in the 1.5 T MR‐linac. Methods: The motion platform was assessed for several magnetic resonance (MR) characteristics, including spurious noise generation and B0&B1 homogeneity. In addition, the motion platform's motion accuracy and beam attenuation were assessed. An application was shown with a ScandiDos Delta4 Phantom+ MR demonstrating patient‐specific plan QA of gated treatments using time‐resolved dosimetry that includes motion based on a patient's respiratory motion trace. Results: All MR characterization measurements were within the set tolerances for MRI QA. The motion platform motion accuracy showed excellent agreement with the reference, with a standard deviation of the amplitude of 0.01 mm (20 kg load) for the motor's self‐estimated positions and 0.22 mm (no load) for the images acquired with the electronic portal imager. Beam attenuation was found to be 11.8%. The combination of the motion platform and Delta4 demonstrated motion‐included dosimetry at high temporal and spatial resolutions. Motion influenced the measured dose in non‐gated treatments by up to −20.1%, while gated deliveries showed differences of up to −1.7% for selected diodes. Conclusion: The motion platform was found to be usable in a 1.5 T magnetic field, and for all MR characterization experiments, no influence from the motion platform was observed. This motion platform enables to perform motion‐included QA, with a measurement device of choice.Keywords
Funding Information
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (18495)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (20827)
- ITEA (20052)
This publication has 19 references indexed in Scilit:
- Treatment planning evaluation and experimental validation of the magnetic resonance-based intrafraction drift correctionPhysics and Imaging in Radiation Oncology, 2024
- Intrafraction Motion Management With MR-Guided Radiation TherapySeminars in Radiation Oncology, 2023
- Gating and intrafraction drift correction on a 1.5 T MR-Linac: Clinical dosimetric benefits for upper abdominal tumorsRadiotherapy and Oncology, 2023
- Reducing PTV margins for prostate SBRT with motion compensation and gating techniquesJournal of Applied Clinical Medical Physics, 2022
- Commissioning of a 1.5T Elekta Unity MR‐linac: A single institution experienceJournal of Applied Clinical Medical Physics, 2020
- Technical design and concept of a 0.35 T MR-LinacClinical and Translational Radiation Oncology, 2019
- Adaptive radiotherapy: The Elekta Unity MR-linac conceptClinical and Translational Radiation Oncology, 2019
- MRI commissioning of 1.5T MR-linac systems – a multi-institutional studyRadiotherapy and Oncology, 2019
- Emerging role of MRI in radiation therapyJournal of Magnetic Resonance Imaging, 2018
- MRI/linac integrationRadiotherapy and Oncology, 2008